Staphylococcus aureus - NRS123
Other designations ( MW2;C1999000459;USA400;99065 )
|
|
|
| Demographic Information: |
|
| Country/State: |
United States / North Dakota |
Date of Isolation: |
01/01/1998 |
| Patient Age: |
1 Year(s) and 4 Month(s) |
Gender: |
Female |
| Patient Location: |
Inpatient |
Patient Service: |
Pediatrics |
| Culture Source: |
Bloodstream |
|
| Phenotypic Properties: |
Methicillin resistance; susceptible to non beta-lactam antibiotics
|
|
| Genotypic Properties: |
Type IVa SCCmec; seh+, seo+; cna+; (lukS-PV-lukF-PV)+;
PFT is USA400, MLST is ST1, spa type is UJJJJFE, agr group III
|
|
|
| Literature Citation: |
MMWR. Aug 20, 1999. CDC 48(32):707-709.
Baba, T. et al. 2002. The Lancet 359:1819-1827.
JCM, 2003, 41:5113-5120.
|
|
| Comment: |
According to report in MMWR, NRS123 was closely related to NRS192, NRS193, and NRS194 by PFGE.
|
| |
| Description: |
A community-acquired MRSA strain sequenced at the National Institute of Technology and Evaluation, Tokyo.
|
|
| Repositories: |
Genome Sequenced Strains
Known Clinically Associated Strains - Others
Molecular Typing Control Strains
|
|
|
|
S = Susceptible; R = Resistant; NS = Not Susceptible; I =Intermediate; N/A = Not Available P= Pending results |
|
|
NARSA Antimicrobial Profile for Other Antimicrobial Agents
|
|
Molecular Characterization Data
|
|
| Ciprofloxacin |
= 0.5 |
S |
| Clindamycin |
= 0.12 |
S |
| Daptomycin |
= 0.5 |
N/A |
| Erythromycin |
= 0.5 |
S |
| Gentamicin |
= 0.5 |
S |
| Linezolid |
= 2 |
S |
| Oxacillin |
> 16 |
R |
| Penicillin |
> 2 |
R |
| Quinupristin/dalfopristin |
= 0.25 |
S |
| Teicoplanin |
= 1 |
S |
| Tetracycline |
= 32 |
R |
| Trimeth/sulfa |
<= 0.25/4.75 |
S |
| Vancomycin |
= 1 |
S |
|
|
|
|
|
|
|
|
